CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.

MLA

Abou-Ayache, Ramzi, et al. “CMV Infections after Two Doses of Daclizumab versus Thymoglobulin in Renal Transplant Patients Receiving Mycophenolate Mofetil, Steroids and Delayed Cyclosporine A.” Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, vol. 23, no. 6, June 2008, pp. 2024–32. EBSCOhost, https://doi.org/10.1093/ndt/gfm873.

APA

Abou-Ayache, R., Büchler, M., Lepogamp, P., Westeel, P.-F., Le Meur, Y., Etienne, I., Lobbedez, T., Toupance, O., Caillard, S., Goujon, J.-M., Bergougnoux, L., & Touchard, G. (2008). CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A. Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, 23(6), 2024–2032. https://doi.org/10.1093/ndt/gfm873

Chicago

Abou-Ayache, Ramzi, Mathias Büchler, Patrick Lepogamp, Pierre-François Westeel, Yannick Le Meur, Isabelle Etienne, Thierry Lobbedez, et al. 2008. “CMV Infections after Two Doses of Daclizumab versus Thymoglobulin in Renal Transplant Patients Receiving Mycophenolate Mofetil, Steroids and Delayed Cyclosporine A.” Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association 23 (6): 2024–32. doi:10.1093/ndt/gfm873.